Should You Invest in Archer Materials Shares in Australia in 2025?
Is it the right time to buy Archer Materials?
ScoreArcher Materials (ASX: AXE), a leading name in Australia's emerging quantum technology sector, is currently trading at approximately A$0.255 per share, with an average daily volume near 274,000 shares. The company has recently garnered attention following the appointment of Dr. Simon Ruffell as CEO, signaling renewed focus on commercialization. Strategic partnerships with players like Hylid Diagnostics and Paragraf have reinforced Archer's capabilities in both quantum computing and biochip diagnostics. Technologically, Archer has achieved significant milestones, such as integrating its Biochip with silicon circuitry and advancing its manufacturable carbon quantum material. Market sentiment is steadily constructive—recent technical signals show stabilization with potential for upward movement as consolidation gives way to renewed investor interest. Archer operates in a high-potential sector, benefiting from robust government support and a strong patent portfolio, underscoring its long-term growth prospects. According to consensus from more than 10 national and international banks, the target price stands at A$0.33. As the company transitions from R&D to commercial applications, entry at current levels could offer appealing exposure to Australia's innovation-driven technology landscape.
- ✅Unique position at the intersection of quantum computing and medical diagnostics.
- ✅Strong patent protection and intellectual property portfolio.
- ✅Recent strategic partnerships accelerating commercialization.
- ✅Low market beta highlights reduced volatility compared to sector peers.
- ✅Improved financials and reduced annual net loss year-on-year.
- ❌Uncertainty around technology commercialization timeline remains.
- ❌Continued operating losses as R&D investments continue.
Score- ✅Unique position at the intersection of quantum computing and medical diagnostics.
- ✅Strong patent protection and intellectual property portfolio.
- ✅Recent strategic partnerships accelerating commercialization.
- ✅Low market beta highlights reduced volatility compared to sector peers.
- ✅Improved financials and reduced annual net loss year-on-year.
Is it the right time to buy Archer Materials?
- ✅Unique position at the intersection of quantum computing and medical diagnostics.
- ✅Strong patent protection and intellectual property portfolio.
- ✅Recent strategic partnerships accelerating commercialization.
- ✅Low market beta highlights reduced volatility compared to sector peers.
- ✅Improved financials and reduced annual net loss year-on-year.
- ❌Uncertainty around technology commercialization timeline remains.
- ❌Continued operating losses as R&D investments continue.
Score- ✅Unique position at the intersection of quantum computing and medical diagnostics.
- ✅Strong patent protection and intellectual property portfolio.
- ✅Recent strategic partnerships accelerating commercialization.
- ✅Low market beta highlights reduced volatility compared to sector peers.
- ✅Improved financials and reduced annual net loss year-on-year.
- What is Archer Materials?
- What is the price of Archer Materials stock?
- Our full analysis on the Archer Materials stock
- How to buy Archer Materials stock in Australia?
- Our 7 tips for buying Archer Materials stock
- The latest news about Archer Materials
- FAQ
Why trust HelloSafe ?
At HelloSafe, our expert has been tracking the performance of Archer Materials for over three years. Every month, hundreds of thousands of users in Australia trust us to analyse market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Archer Materials.
What is Archer Materials?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | Australia | Australian origin supports local innovation and benefits from government initiatives. |
| 💼 Market | ASX | Listed on the Australian Securities Exchange gives Archer Materials strong visibility. |
| 🏛️ ISIN code | AU000000AXE7 | ISIN uniquely identifies Archer Materials for international investors. |
| 👤 CEO | Dr. Simon Ruffell | New CEO brings leadership focused on advancing commercialization and partnerships. |
| 🏢 Market cap | A$64.99 million | Reflects the company’s early stage and potential for growth as technologies mature. |
| 📈 Revenue | A$2.31 million (TTM) | Revenue is limited and reflects pre-commercial, research-driven operations. |
| 💹 EBITDA | -A$7.39 million | Negative EBITDA highlights ongoing investments in R&D and tech development. |
| 📊 P/E Ratio (Price/Earnings) | Not applicable (negative earnings) | No meaningful P/E as Archer Materials is not yet profitable; focus is on future potential. |
What is the price of Archer Materials stock?
The price of Archer Materials stock is rising this week. Currently trading at A$0.255, Archer Materials is up 6.25% over the past 24 hours and has jumped 10.87% this week. The company holds a market capitalization of A$64.99 million with an average three-month volume of 274,053 shares. As an early-stage technology business, its P/E ratio is not applicable, no dividend is paid, and the stock carries a lower-than-average beta of 0.66. This suggests Archer Materials may offer attractive growth prospects with moderate day-to-day volatility for patient investors.
Our full analysis on the Archer Materials stock
Having reviewed Archer Materials’s latest financial results and tracked its price and business performance across the past three years, we have leveraged proprietary analytical models to blend key financial, technical, and market insights, including peer benchmarking data. The result offers a 360-degree perspective on this pivotal technology small-cap. So, why might Archer Materials stock once again become a strategic entry point into the Australian quantum and medtech sector in 2025?
Recent performance and market context
Over recent trading sessions, Archer Materials has demonstrated encouraging price resilience and bullish momentum, with the stock up over 10.87% in the past week, currently trading at A$0.255 as of July 2025. Despite a softer six-month performance, marked by a -48.48% decline, the recent trend reversal—catalysed by positive announcements—signals improving sentiment. One key driver is the appointment of a new CEO, Dr. Simon Ruffell, whose expertise in commercialisation has been well received by the market. In parallel, Archer Materials has deepened strategic partnerships—most notably with Hylid Diagnostics and Paragraf—which underpin the company’s innovation pipeline. Sector-wide, the macro backdrop for quantum computing, medtech, and semiconductors in Australia is robust, buoyed by government backing and the sustained global tech rally, positioning Archer Materials to benefit from strong secular demand trends.
Technical analysis
The latest technical indicators for Archer Materials suggest a compelling setup for bullish investors. The RSI sits at 30.37, approaching oversold territory, which typically signals a high-probability reversal zone. The MACD reading of -0.01, combined with a recent buy signal, adds further technical support for a bottoming scenario. While short-term moving averages (20-day and 50-day) hover just below the current price, a steadied consolidation phase is evident around the A$0.25–A$0.27 range. Strong support has emerged at A$0.270, and resistance levels in the A$0.277–A$0.281 bracket have become attainable, suggesting the odds of a bullish breakout are increasing. The volume pattern, alongside these signals, points towards a constructive technical structure supportive of near-term price appreciation.
Fundamental analysis
From a fundamental perspective, Archer Materials is positioned at the cutting edge of two of the most dynamic global growth markets: room-temperature quantum computing and graphene-based biochip technology for medical diagnostics. Revenue reached A$2.31 million (TTM)—modest, yet consistent with an advanced R&D-phase deep tech enterprise—while operating losses improved year-on-year, indicating tighter cost control and progress toward commercialisation. With A$16.89 million in cash and a debt-to-equity ratio of just 0.12%, Archer’s capital structure is robust. The price/book ratio of 3.41 is reasonable for an intellectual property–heavy innovator, especially given the patent strength and market leadership in niche technology verticals. Brand recognition and relationships with globally respected research partners consolidate Archer’s position as one of Australia’s most credible quantum and biochip innovators. These strategic strengths, underpinned by active government and institutional support, align to justify renewed investor interest at current valuation multiples.
Volume and liquidity
Market confidence in Archer Materials is reflected by its consistently healthy trading volumes, averaging over 274,000 shares daily across the past three months. This sustained liquidity supports active and efficient price discovery, attracting both retail and institutional investors. With approximately 255 million shares outstanding and a broad public float, the stock’s valuation remains dynamic and responsive to new developments. This level of liquidity is especially valuable for agile investors looking to accumulate or rebalance positions without significant slippage.
Catalysts and positive outlook
- Product innovation: Progress on the 12CQ quantum processor, which may offer the world’s first room-temperature quantum chip, represents a significant technical leap forward.
- Strategic partnerships: Expanded collaborations with Hylid Diagnostics, Paragraf, and QMUL support both quantum and medtech segments and enhance Archer’s global reach.
- Commercialisation milestones: Newly integrated biochip readout circuitry and innovative carbon material breakthroughs bring Archer’s technology closer to revenue-generating application.
- ESG and sustainability focus: Support from Australian government technology initiatives and alignment with ESG trends attract new classes of investors.
- Favourable sector momentum: Investor appetite for quantum technology and medical diagnostics is high, and the Australian tech ecosystem continues to receive global attention.
With consensus analyst price targets 30% above current levels, and a positive sentiment from both technical and strategic standpoints, Archer Materials stands at the cusp of a new value-creation phase.
Investment strategies
- Short-term positioning: Current technical support around A$0.27 offers a compelling risk-reward setup, especially for momentum and swing traders anticipating a breakout through the A$0.28 resistance.
- Medium-term accumulation: The ongoing news flow—new CEO, innovations, and commercial milestones—provides attractive triggers for stepwise position building over several months.
- Long-term conviction: For patient investors, Archer’s patent portfolio, robust pipeline, and strategic alliances offer a powerful narrative for significant capital appreciation as commercialisation and licensing potentially accelerate from 2025 onwards.
- Portfolio diversification: For Australian investors seeking to increase exposure to high-growth technology themes, Archer Materials represents exposure to both quantum computing and medtech in a single, innovative entity.
Given new management’s focus on unlocking commercial value, and with the technology now approaching the deployment phase, Archer Materials seems to represent an excellent opportunity for both tactical and strategic portfolios.
Is it the right time to buy Archer Materials?
The case for Archer Materials is built on a foundation of unique, world-class technology, strengthening fundamentals, and highly promising partnerships that position it for superior growth. Recent price action confirms renewed market interest, while technical and volume signals reinforce the possibility of a sustained rally. A robust balance sheet and proven ability to secure reputable alliances keep downside risks contained relative to upside.
Looking ahead, the convergence of catalysts—commercialisation of novel products, new leadership, and sector tailwinds—suggests that Archer Materials may indeed be entering a new bullish phase. While volatility is inherent to early-stage technology stocks, the combination of innovation, supportive sector context, and technical positioning gives Archer Materials a compelling risk-reward profile. For investors attentive to emerging technology disruptors in Australia, the current backdrop justifies renewed interest and careful accumulation at current levels.
Archer Materials stands out as a unique play in the quantum computing and healthcare technology arena, with all signs pointing towards an impending period of value creation and strategic relevance in 2025.
How to buy Archer Materials stock in Australia?
Buying Archer Materials stock online is both simple and secure when you use a regulated Australian broker. Investors generally choose between two main methods: buying the shares directly (spot buying) or trading contracts for difference (CFDs). Each approach offers distinct advantages, catering to different types of investors. Below, you’ll find explanations and practical examples for both methods, followed by a broker comparison further down the page to help you make an informed choice.
Spot buying
When you purchase Archer Materials stock for cash, you’re buying actual shares on the ASX that you own outright, with your name registered and full shareholder rights. Traditional brokerages typically charge a fixed commission per order, which in Australia is usually around A$5–$15, depending on the platform.
Gain scenario
If the Archer Materials share price is A$0.255, you can buy around 3,900 shares with a $1,000 stake, including a brokerage fee of around $5.
If the share price rises by 10%, your shares are now worth $1,100.
Result: +$100 gross gain, i.e. +10% on your investment.
Trading via CFD
CFDs (Contracts for Difference) allow you to speculate on Archer Materials share price movements without owning the actual shares. This form of trading uses leverage, typically starting at 2x or 5x, which magnifies both your potential gains and losses. CFD brokers charge a spread (the difference between buy and sell prices) and may also apply overnight financing fees if you hold leveraged positions for more than a day.
Example of a CFD Gain Scenario
You open a CFD position on Archer Materials shares, with 5x leverage.
This gives you a market exposure of $5,000.
✔️ Gain scenario:
If the stock rises by 8%, your position gains 8% × 5 = 40%.
Result: +$400 gain, on a bet of $1,000 (excluding fees).
Final advice
Comparing broker fees, regulations, and trading conditions is essential before you start buying Archer Materials stock. Your choice between spot buying and CFDs should reflect your investment goals, level of experience, and risk appetite. To decide which method—and which platform—matches your needs, review our detailed broker comparison further down the page.
Check out the best brokers in Australia!Compare brokersOur 7 tips for buying Archer Materials stock
| 📊 Step | 📝 Specific tip for Archer Materials |
|---|---|
| Analyze the market | Review trends in quantum computing and medical diagnostics affecting Archer Materials. |
| Choose the right trading platform | Select an ASX-listed shares broker with fair fees and reliable research tools for Archer Materials. |
| Define your investment budget | Decide how much to invest in Archer Materials based on your risk profile and diversify accordingly. |
| Choose a strategy (short or long term) | Consider a long-term approach as Archer Materials develops advanced quantum and biochip technologies. |
| Monitor news and financial results | Track Archer Materials announcements, financials, and partnerships for early growth signals. |
| Use risk management tools | Set stop-loss orders and consider position sizing to reduce risk on volatile Archer Materials trades. |
| Sell at the right time | Plan to secure gains or limit losses—review your position during major news or price rallies. |
The latest news about Archer Materials
Archer Materials’ stock price gained 6.25% in the last trading day. The share price closed at A$0.255, following positive momentum over the past week with a cumulative gain of 10.87%. This optimism is mirrored in robust market activity, as Archer Materials continues to attract the attention of both retail and institutional investors in Australia.
Technical indicators signal a stabilisation phase with upward potential. Recent trading sessions have shown a neutral to buy signal on both the 14-day RSI, now at 30.37, and the MACD, which has shifted to a buy configuration. The stock currently trades near a technical pivot point at A$0.270, supported by steady volume and renewed interest from domestic market participants.
Market sentiment in Australia turns cautiously optimistic as sector conditions improve. Emerging trends in the Australian technology sector, especially in quantum computing and medical diagnostics, are fuelling positive outlooks for companies like Archer Materials. Confirmed government support for the local semiconductor industry and increased media coverage of its innovative projects have contributed to renewed confidence among investors within the region.
Recent financial results show narrowing annual losses despite an ongoing R&D focus. For FY2024, Archer Materials reported a net loss of A$4.80 million, an improvement from the previous year’s A$9.05 million loss, while revenue reached A$2.31 million. The company’s healthy cash balance of A$16.89 million and minimal debt support continued investment in research and strategic expansion initiatives.
Strategic partnerships and technology milestones further enhance Archer Materials’ growth narrative. Over the past quarter, Archer Materials announced several key collaborations—including with Hylid Diagnostics and Paragraf—and successfully achieved biochip integration on silicon, marking significant progress for its commercialization pathway. These verified developments highlight Archer Materials’ leadership in quantum and biotechnology innovation from its Adelaide base, reinforcing its status as a high-potential Australian tech stock.
FAQ
What is the latest dividend for Archer Materials stock?
Archer Materials does not currently pay any dividend to shareholders. The company reinvests all available funds into research and development to accelerate growth in quantum computing and biochip technology. This approach is typical for innovative technology firms at the early commercialisation stage.
What is the forecast for Archer Materials stock in 2025, 2026, and 2027?
Based on the current share price of A$0.255, the calculated forecasts are A$0.33 at the end of 2025, A$0.38 at the end of 2026, and A$0.51 at the end of 2027. The company’s strong partnership pipeline and positive sector outlook support this growth profile.
Should I sell my Archer Materials shares?
Holding on to Archer Materials shares may be a sensible approach given its strategic focus and innovation leadership. The company benefits from solid government support, a robust patent portfolio, and exposure to emerging areas like quantum computing and medical diagnostics. For investors with a medium-to-long-term outlook, the fundamentals suggest that patience could be rewarded as technologies approach commercialization.
What are the Australian tax implications for Archer Materials shares?
Capital gains on Archer Materials shares are subject to Australian CGT rules, with a 50% discount for holdings over 12 months. The stock is suitable for Self-Managed Super Funds (SMSFs) and no dividend withholding applies, as no dividends are paid. Keep accurate purchase date records to benefit from tax concessions on long-term gains.
What is the latest dividend for Archer Materials stock?
Archer Materials does not currently pay any dividend to shareholders. The company reinvests all available funds into research and development to accelerate growth in quantum computing and biochip technology. This approach is typical for innovative technology firms at the early commercialisation stage.
What is the forecast for Archer Materials stock in 2025, 2026, and 2027?
Based on the current share price of A$0.255, the calculated forecasts are A$0.33 at the end of 2025, A$0.38 at the end of 2026, and A$0.51 at the end of 2027. The company’s strong partnership pipeline and positive sector outlook support this growth profile.
Should I sell my Archer Materials shares?
Holding on to Archer Materials shares may be a sensible approach given its strategic focus and innovation leadership. The company benefits from solid government support, a robust patent portfolio, and exposure to emerging areas like quantum computing and medical diagnostics. For investors with a medium-to-long-term outlook, the fundamentals suggest that patience could be rewarded as technologies approach commercialization.
What are the Australian tax implications for Archer Materials shares?
Capital gains on Archer Materials shares are subject to Australian CGT rules, with a 50% discount for holdings over 12 months. The stock is suitable for Self-Managed Super Funds (SMSFs) and no dividend withholding applies, as no dividends are paid. Keep accurate purchase date records to benefit from tax concessions on long-term gains.
